Pharmacometabolomics in Drug Disposition, Toxicity, and Precision Medicine
- 16 January 2024
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (11) , 1187-1195
Abstract
The precision medicine initiative has driven a substantial change in the way scientists and health care practitioners think about diagnosing and treating disease. While it has long been recognized that drug response is determined by the intersection of genetic, environmental and disease factors, improvements in technology have afforded precision medicine guided dosing of drugs to improve efficacy and reduce toxicity. Pharmacometabolomics aims to evaluate small molecule metabolites in plasma and/or urine to help evaluate mechanisms that predict and/or reflect drug efficacy and toxicity. In this mini review, we provide an overview of pharmacometabolomic approaches and methodologies. Relevant examples where metabolomic techniques have been used to better understand drug efficacy and toxicity in major depressive disorder and cancer chemotherapy are discussed. In addition, the utility of metabolomics in drug development and understanding drug metabolism, transport and pharmacokinetics is reviewed. Pharmacometabolomic approaches can help understand factors mediating drug disposition, efficacy and toxicity. While important advancements in this area have been made, their remain several challenges that must be overcome before this approach can be fully implemented into clinical drug therapy. Significance Statement Pharmacometabolomics has emerged as an approach to identify metabolites that allow for implementation of precision medicine approaches to pharmacotherapy. This review article provides an overview pharmacometabolomics including highlights of important examples.Keywords
This publication has 75 references indexed in Scilit:
- N1‐Methylnicotinamide as Biomarker for MATE‐Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and ProbenecidClinical Pharmacology & Therapeutics, 2023
- Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With DepressionJAMA Network Open, 2020
- PharmVar GeneFocus: CYP2D6Clinical Pharmacology & Therapeutics, 2019
- Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?Clinical Pharmacology & Therapeutics, 2019
- The integration of LC‐MS and NMR for the analysis of low molecular weight trace analytes in complex matricesMass Spectrometry Reviews, 2018
- Identification of ω‐ or (ω‐1)‐Hydroxylated Medium‐Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A ActivityClinical Pharmacology & Therapeutics, 2017
- Metabolomic and Genome‐wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1Clinical Pharmacology & Therapeutics, 2016
- Metabolomics by Gas Chromatography–Mass Spectrometry: Combined Targeted and Untargeted ProfilingCurrent Protocols in Molecular Biology, 2016
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer NetworkCancer, 2012
- Mass spectrometry‐based metabolomicsMass Spectrometry Reviews, 2006